DEC 12, 2017 10:00 AM PST
WEBINAR: Gold Standards and innovative processes for DC research in immuno-oncology
SPONSORED BY: Miltenyi Biotec
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
7 6 1441

Speakers:
  • R&D Manager: Dendritic Cell & B cells
    Biography
      Dr. Dzionek is an immunologist and serves as a head of R&D Reagents-Immunotherapy at Miltenyi Biotec GmbH. Dr. Dzionek completed his M.S. degree in Biology in the group of Prof. Andreas Radbruch in 1998 and earned his PhD in basic immunology from the University of Cologne in 2003. He is now working for more than 15 years in the field of dendritic cells focusing on the specific functions of different dendritic cell subsets. During his PhD thesis, he discovered and functionally characterized a number of blood dendritic cell specific receptors including BDCA‐1, 2, 3 and 4, which became a state of the art marker for human dendritic cell subsets. His work on BDCA‐2 at AmCell Corporation in Sunnyvale, CA and in the group of Marco Colonna and Marina Cella at Basel Institute for Immunology provided the basis for the clinical development of the BDCA‐2‐specific antibody for the use in interferon alpha driven autoimmune diseases, which is currently being tested under his supervision in the phase I clinical trial. His group at Miltenyi Biotec GmbH develops assays, tools and reagents for research and clinical‐scale separation and analysis of dendritic cells, B‐cells and tumor reactive T-cells.

    Abstract:

    DATE: December 12, 2017
    TIME: 10:00AM PT

    Since their discovery, dendritic cells (DCs) have demonstrated a central role in the development of effective immune responses. Their unique ability to induce T cells responses to unknown antigens made them interesting research targets. However, DCs are not an easy cell type to study due to their low frequency in the periphery, lack of univocal lineage markers and the fact that they cannot be expanded in vitro. Artificial systems have been developed to obtain DC-like cells in numbers compatible with their study. The standard is to generate DCs from peripheral blood progenitors. This method has been instrumental in developing not only our basic understanding of these cells but also in translational aspects. Although the safety profile of DC approaches  has been proven in several trials and objective responses were observed, their study has been hindered by technical difficulties, especially in clinical settings. Recently, individual DCs subtypes have been shown to respond differently to specific pathogen and tumor environments and that they may functionally complement each other to evoke an effective immune response.
    The recent progress in immuno-oncology and the rapid development of new drugs, give us potential to design novel and effective combination strategies to contrast the complex tumor settings. DCs may be an invaluable part of approaches aiming at targeting several checkpoints of anti-tumoral immune responses. To facilitate translational studies with DCs we developed state of the art automated and closed processes to obtain clinical scale DCs, reagents produced under good manufacturing practice (GMP) and analysis tools. In this webinar we will illustrate the CliniMACS Prodigy LP-14 System for generation of monocyte-derived DCs and the innovative LP-BDC for isolation and activation of primary DCs to investigate their clinical potential.

    Learning Objectives:

    • Review recent progress in immuno-oncology
    • Review generation of monocyte-derived DCs 

     

    The CliniMACS System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are manufactured and controlled under an ISO 13485-certified quality system. In the EU, the CliniMACS System components are available as CE-marked medical devices. In the US, the CliniMACS Prodigy LP-14 System is for research use only. CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research only and not for therapeutic or diagnostic use. CliniMACS, CliniMACS Prodigy, and MACS® are registered trademarks of Miltenyi Biotec GmbH. Copyright© 2017 Miltenyi BiotecPRO. All rights reserved.


    Show Resources
    Loading Comments...